SIMONELLI, Matteo
 Distribuzione geografica
Continente #
NA - Nord America 3.342
EU - Europa 831
AS - Asia 211
AF - Africa 117
Continente sconosciuto - Info sul continente non disponibili 6
SA - Sud America 5
OC - Oceania 2
Totale 4.514
Nazione #
US - Stati Uniti d'America 3.305
FI - Finlandia 220
IE - Irlanda 161
IT - Italia 126
NG - Nigeria 117
DE - Germania 84
CN - Cina 83
FR - Francia 66
SE - Svezia 63
SG - Singapore 52
NL - Olanda 46
CA - Canada 37
GB - Regno Unito 29
TR - Turchia 29
IL - Israele 19
BE - Belgio 15
IN - India 14
CL - Cile 5
EU - Europa 4
IR - Iran 4
PL - Polonia 4
CH - Svizzera 3
RU - Federazione Russa 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
AT - Austria 2
AU - Australia 2
ES - Italia 2
HK - Hong Kong 2
BG - Bulgaria 1
JP - Giappone 1
KR - Corea 1
MD - Moldavia 1
MK - Macedonia 1
NO - Norvegia 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
UA - Ucraina 1
Totale 4.514
Città #
Wilmington 706
Chandler 508
San Mateo 299
Helsinki 220
Ann Arbor 189
Dublin 161
New York 161
Ashburn 145
Lawrence 127
Princeton 127
Leawood 119
Benin City 117
Woodbridge 81
Shanghai 74
Milan 67
Paris 66
Fairfield 60
Phoenix 55
Boardman 53
Singapore 50
Amsterdam 40
Toronto 35
Kocaeli 29
London 25
San Diego 21
Seattle 21
Brussels 15
Los Angeles 14
Pune 13
Norwalk 12
Santa Clara 9
Abbiategrasso 8
Monmouth Junction 8
Genoa 6
Des Moines 5
Nanjing 5
Redmond 5
Beijing 4
Falkenstein 4
Redwood City 4
Zwolle 4
Cambridge 3
Clearwater 3
Raleigh 3
Taipei 3
Almelo 2
Cupertino 2
Hanover 2
Hong Kong 2
Poznan 2
Sacramento 2
Tappahannock 2
Viterbo 2
Andover 1
Asbest 1
Augusta 1
Berlin 1
Borås 1
Buffalo 1
Chisinau 1
Everett 1
Falkenberg 1
Gorgonzola 1
Hockessin 1
Indianapolis 1
Jacksonville 1
Kemerovo 1
Köln 1
Laval 1
Leipzig 1
Manchester 1
Montréal 1
Moscow 1
Newark 1
Niles 1
Nuremberg 1
Pittsfield 1
San Jose 1
Seoul 1
Tehran 1
Torino 1
Valladolid 1
Vienna 1
Warsaw 1
Totale 3.731
Nome #
Association of Supratotal Resection with Progression-Free Survival, Malignant Transformation, and Overall Survival in Lower-Grade Gliomas 66
Carbon-11-methionine PET-CT as an imaging biomarker in brain gliomas eligible for surgery 65
Cerebrospinal fluid tumor DNA for liquid biopsy in glioma patients’ management: close to clinic 59
Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. 56
Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study 56
Role of Myeloid Cells in the Immunosuppressive Microenvironment in Gliomas 55
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 54
COVID-19 and liver cancer clinical trials: not everything is lost 53
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 53
Administration of temozolomide during and after radiotherapy for newly diagnosed high-grade gliomas excluding glioblastoma multiforme 53
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors 52
Addition of temozolomide to radiotherapy for treatment of newly diagnosed anaplastic gliomas 52
Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1 in patients with hepatocellular carcinoma 52
Second-line chemotherapy in malignant pleural mesothelioma: Results of a retrospective multicenter survey 51
Targeted therapy for thymic epithelial tumors: a new horizon ? Review of the literature and two cases reports 51
FDG-PET as a tool to optimize residual surgery in patients with primary extragonadal germ cell tumors: preliminary results 51
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF 51
Thymoma associated with myasthenia and autonomic anti-Hu paraneoplastic neuropathy 50
Multimodal Characterization of Supratentorial Gliomas: Relationship Among Morphological, Metabolic and Molecular features 50
Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top" 50
Correlation of microvascular fractal dimension with positron emission tomography [C-11]-methionine uptake in glioblastoma multiforme: Preliminary findings 49
Pathological characterization of nivolumab –related liver injury in a patient with glioblastoma 49
Advances in the biology of malignant pleural mesothelioma 49
Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma 48
Reproducibility of the WHO classification of thymomas: practical implications 48
Infertility risk and teratogenicity of molecular targeted anticancer therapy: a challenging issue 47
Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma 47
The 70-year-old newly diagnosed glioblastoma patients are older than the 65-year-old? Outcome evaluation of the two categories in a matched case control study with propensity score balancing 47
Expression of the transcription factor HEY1 in glioblastoma: a preliminary clinical study 46
HIGH-GRADE GLIOMAS AND IMMUNOTHERAPEUTIC EARLY PHASE CLINICAL TRIALS: A SINGLE-CENTER EXPERIENCE 46
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 46
Conducting Phase I Trials During the SARS-Coronavirus-2 Outbreak: About Science and Care 46
High-grade gliomas (HGGs) and immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 45
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in a observational study 45
Role of surgical resection in recurrent glioblastoma: prognostic factors and outcome evaluation in an observational study. 45
Neutrophils in Gliomas 44
Checkpoint Inhibitors as High-Grade Gliomas Treatment: State of the Art and Future Perspectives 44
Electrolyte abnormalities and side effects of zoledronate in patients with bone metastases 43
Prognostic and predictive role of [F-18]fluorodeoxyglucose positron emission tomography (FDG-PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up-front pemetrexed-based chemotherapy 43
Thymidylate Synthase and Excision Repair Cross-Complementing Group-1 as Predictors of Responsiveness in Mesothelioma Patients Treated with Pemetrexed/Carboplatin 43
Insulin-Like Growth Factor-1 Receptor and Phosphorylated AKT-Serine 473 Expression in 132 Resected Thymomas and Thymic Carcinomas 42
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report 42
A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis 41
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma 41
Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study 41
Is supratotal resection achievable in low-grade gliomas? Feasibility, putative factors, safety, and functional outcome. 40
Is surgical resection useful in elderly newly diagnosed glioblastoma patients? Outcome evaluation and prognostic factors assessment 40
Editorial for "Noninvasive Assessment of MGMT Promoter Methylation Status in World Health Organization Grade II-IV Glioma Using Histogram Analysis of Inflow-Based Vascular-Space Occupancy Combined with Structural MR Imaging" 40
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 40
Herpes infections in breast cancer patients treated with adjuvant chemotherapy 39
HYPOFRACTIONATED RADIATION THERAPY (OVER 3 WEEKS) CAN REPLACE CONVENTIONAL RADIATION THERAPY SCHEDULE (OVER 6 WEEKS) IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? THE TIMES ARE RIPE 39
Multimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma 38
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 38
The Role of Pemetrexed in the Pharmacotherapy of Malignant Pleural Mesothelioma 38
Lower Grade Gliomas: Relationships Between Metabolic and Structural Imaging with Grading and Molecular Factors 37
Value of Surgical Resection in Patients with Newly Diagnosed Grade III Glioma Treated in a Multimodal Approach: Surgery, Chemotherapy and Radiotherapy 37
Imaging biomarkers in primary brain tumours 37
Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution 36
VINORELBINE (V) IN PEMETREXED-PRETREATED PATIENTS (PTS) WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 36
Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review. 36
Depatuxizumab Mafodotin (Depatux-M) Plus Temozolomide in Recurrent Glioblastoma Patients: Real-World Experience from a Multicenter Study of Italian Association of Neuro-Oncology (AINO) 36
Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series 35
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal 35
Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-Mutations 34
Supratotal resection in newly diagnosed GBMs: role of this surgical strategy beyond enhancing boundaries 33
Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma 33
Outcome evaluation of patients with diagnosed WHO grade III glioma treated according to the molecular profile, the hystology, and the extent of resection (EOR) 33
Three-day low-dose Cisplatin administration in advanced non-small cell lung cancer (NSCLC): Efficacy and reduced toxicity 33
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors 33
THE ROLE OF THYMIDTYLATE SYNTHASE (TS) AND EXCISION REPAIR CROSS-COMPLEMENTING GROUP 1 (ERCC1) IMMUNOHISTOCHEMICAL EXPRESSION IN MALIGNANT PLEURAL MESOTHELIOMA (MPM) PATIENTS TREATED WITH PEMETREXED AND CARBOPLATIN 33
High incidence of hypocalcemia in patients with bone metastases from different kinds of neoplasms, treated with zoledronate 32
Future developments in the management of malignant pleural mesothelioma 32
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S) 32
Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience 31
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 31
Reliability of the HER2 status assessment by immunohistochemistry for breast cancer patients after preoperative chemotherapy 31
Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients 31
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient A CARE-compliant case report 31
Isatuximab plus atezolizumab in patients with advanced solid tumors: results from a phase I/II, open-label, multicenter study 30
Optimizing residual surgery for patients with primary extragonadal germ cell tumors 30
PHASE I AND PHARMACODYNAMIC STUDY OF NGR-HTNF ADMINISTERED AT HIGH DOSES IN REFRACTORY PATIENTS WITH SOLID TUMORS 30
Newly diagnoses grade III glioma patients: evaluation of factors conditioning outcome 30
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 30
Prognostic relevance of temporal muscle thickness as a marker of sarcopenia in patients with glioblastoma at diagnosis 30
Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC) 29
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors 29
High-dose chemotherapy followed by autologous hematopoietic stem-cell transplantation for the treatment of solid tumors in adults: a critical review 29
Outcome of high-grade gliomas (HGGs) treated into immunotherapeutic early-phase clinical trials (ieCTs): A single-center experience 28
Retreatment with pemetrexed-based chemotherapy (PBC) in patients with malignant pleural mesothelioma (MPM): An observational study 28
IMPACT OF SOLUBLE TUMOR NECROSIS FACTOR-RECEPTORS (STNF-RS) SHEDDING ON OUTCOME IN PATIENTS TREATED WITH NGR-HTNF 28
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with refractory solid tumours 28
Tivantinib in combination with Carboplatin and Pemetrexed as first line treatment in patients with advanced non-squamous NSCLC or Malignant Pleural Mesothelioma: results of phase I trial 28
IS SURGICAL RESECTION USEFUL IN ELDERLY NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS? OUTCOME EVALUATION AND PROGNOSTIC FACTORS ASSESMENT 27
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 27
Vinorelbine as Second or Third-Line Therapy in Pemetrexed-Pretreated Malignant Pleural Mesothelioma (MPM) Patients 27
Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors 27
Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours 27
Final results from ARQ 197-114: A phase 1b safety trial evaluating ARQ 197 in cirrhotic patients (pts) with hepatocellular carcinoma (HCC) 27
Phase Lib trial of tivantinib in combination with carboplatin and pernetrexed as first-line treatment in patients (pts) with advanced nonsquamous NSCLC or malignant pleural mesotheliorna (MPM) 25
PHASE II STUDY OF THE COMBINATION OF BEVACIZUMAB PLUS PEMETREXED AND CARBOPLATIN AS FIRST-LINE THERAPY IN PATIENTS WITH MALIGNANT PLEURAL MESOTHELIOMA (MPM) 25
Totale 3.986
Categoria #
all - tutte 35.520
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.520


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202044 0 0 0 0 0 0 0 0 0 0 1 43
2020/20211.426 47 10 19 8 11 395 184 99 281 185 17 170
2021/2022689 32 5 13 139 4 6 28 102 55 71 199 35
2022/20231.535 285 66 162 148 120 99 3 119 261 153 106 13
2023/2024951 58 108 169 39 45 248 88 50 11 32 103 0
Totale 4.645